Christian B. Dinneen-Long
Algemeen Adviseur bij GLYCOMIMETICS, INC.
Actieve functies van Christian B. Dinneen-Long
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GLYCOMIMETICS, INC. | Algemeen Adviseur | 29-04-2019 | - |
| Bedrijfssecretaris | 29-04-2019 | - |
Loopbaan van Christian B. Dinneen-Long
Eerdere bekende functies van Christian B. Dinneen-Long
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Algemeen Adviseur | - | - |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Algemeen Adviseur | - | - |
| Medimmune, Inc. | Algemeen Adviseur | - | - |
Opleiding van Christian B. Dinneen-Long
| Chicago-Kent College of Law | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| General Counsel | 4 |
| Corporate Secretary | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| Medimmune, Inc. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
